CA2293706C - N-substituted urea inhibitors of farnesyl-protein transferase - Google Patents

N-substituted urea inhibitors of farnesyl-protein transferase Download PDF

Info

Publication number
CA2293706C
CA2293706C CA002293706A CA2293706A CA2293706C CA 2293706 C CA2293706 C CA 2293706C CA 002293706 A CA002293706 A CA 002293706A CA 2293706 A CA2293706 A CA 2293706A CA 2293706 C CA2293706 C CA 2293706C
Authority
CA
Canada
Prior art keywords
aryl
compound
alkyl
heterocycloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002293706A
Other languages
English (en)
French (fr)
Other versions
CA2293706A1 (en
Inventor
Stacy Remiszewski
Alan K. Mallams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2293706A1 publication Critical patent/CA2293706A1/en
Application granted granted Critical
Publication of CA2293706C publication Critical patent/CA2293706C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA002293706A 1997-06-17 1998-06-15 N-substituted urea inhibitors of farnesyl-protein transferase Expired - Fee Related CA2293706C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17
US08/877,049 1997-06-17
PCT/US1998/011507 WO1998057948A1 (en) 1997-06-17 1998-06-15 Novel n-substituted urea inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
CA2293706A1 CA2293706A1 (en) 1998-12-23
CA2293706C true CA2293706C (en) 2008-11-18

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293706A Expired - Fee Related CA2293706C (en) 1997-06-17 1998-06-15 N-substituted urea inhibitors of farnesyl-protein transferase

Country Status (14)

Country Link
EP (1) EP0989979A1 (enExample)
JP (1) JP2002506444A (enExample)
KR (1) KR20010013881A (enExample)
CN (1) CN1267291A (enExample)
AR (1) AR013094A1 (enExample)
AU (1) AU8253598A (enExample)
CA (1) CA2293706C (enExample)
CO (1) CO4940458A1 (enExample)
HU (1) HUP0002954A3 (enExample)
IL (1) IL133389A0 (enExample)
NZ (1) NZ501571A (enExample)
PE (1) PE82799A1 (enExample)
WO (1) WO1998057948A1 (enExample)
ZA (1) ZA985205B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6777415B2 (en) * 2000-10-05 2004-08-17 George Q. Daley Methods of inducing cancer cell death and tumor regression
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
JP4769082B2 (ja) * 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
AU2014239542A1 (en) * 2013-03-15 2015-10-01 Araxes Pharma Llc Covalent inhibitors of KRas G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Rasの阻害剤をスクリーニングするための方法
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体kras、hrasまたはnrasの調節因子としてのキナゾリン誘導体
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
EP1380581A1 (en) * 1995-12-22 2004-01-14 Schering Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases
ID22156A (id) * 1996-09-13 1999-09-09 Schering Corp Turunan substitusi benzosikloheptapiridina yang berguna untuk menghambat fernesil protein transferase
JP2001500515A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な化合物

Also Published As

Publication number Publication date
WO1998057948A1 (en) 1998-12-23
HUP0002954A2 (hu) 2001-06-28
AU8253598A (en) 1999-01-04
CA2293706A1 (en) 1998-12-23
IL133389A0 (en) 2001-04-30
AR013094A1 (es) 2000-12-13
HUP0002954A3 (en) 2002-11-28
CN1267291A (zh) 2000-09-20
KR20010013881A (ko) 2001-02-26
NZ501571A (en) 2002-02-01
CO4940458A1 (es) 2000-07-24
EP0989979A1 (en) 2000-04-05
PE82799A1 (es) 1999-08-26
JP2002506444A (ja) 2002-02-26
ZA985205B (en) 1998-12-15

Similar Documents

Publication Publication Date Title
CA2293706C (en) N-substituted urea inhibitors of farnesyl-protein transferase
US6358968B1 (en) N-substituted urea inhibitors of farnesyl-protein transferase
WO1998057946A1 (en) Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors)
CA2293672C (en) Tricyclic keto amide derivatives useful as farnesyl protein transferase inhibitors
EP0927181A1 (en) Tricyclic compounds useful as fpt inhibitors
CA2293358C (en) Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
US6218401B1 (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
AU5196698A (en) Compounds useful for inhibition of farnesyl protein transferase
US6426352B1 (en) Sulfonamide inhibitors of farnesyl-protein transferase
CA2261724C (en) Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase
CA2293553C (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
MXPA99012069A (en) Novel n-substituted urea inhibitors of farnesyl-protein transferase
CA2293549C (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
EP0927179B1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
CA2293373C (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
MXPA99012080A (en) Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase
HK1023339B (en) Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase
MXPA99012084A (en) Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
MXPA99012087A (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed